Plain-English translation of NCT06723080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing VC005, a new tablet treatment for adults with moderate to severe atopic dermatitis—a chronic skin condition that causes intense itching, redness, and discomfort. The study will compare two different doses of this medication against a placebo (inactive pill) to see which works best and is safest. About 480 people will participate across multiple medical centers.
Many people with moderate to severe atopic dermatitis don't get enough relief from current topical treatments (creams and lotions applied to the skin). This trial is exploring whether this new oral medication might offer better control of symptoms for those who haven't responded well to existing options.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either a low dose of the medication, a high dose, or a placebo—and neither you nor the study team will know which one you're getting. You'll take tablets as directed and visit the study clinic regularly for check-ups, skin assessments, and blood tests. The trial evaluates how well the treatment works and monitors you for any side effects over the course of the study.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Jiangsu vcare pharmaceutical technology co., LTD
Enrollment target
~480 participants
Started
December 2024
Primary completion
August 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
xiaojuan Lai
Chinese Academy of Medical Sciences Hospital of Skin Disease
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.